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Summary. Since vascular resistance is elevated in hy- 
pertension, it is suggested that vasodilators lower the 
blood pressure by a physiologic mechanism and there- 
fore must be more useful than cardiac output-lowering 
drugs. This is not entirely correct. Drugs that lower car- 
diac output are also relative vasodilators, but the vasodi- 
lation occurs at a lower level of cardiac output. It is also 
not necessarily true that all vasodilators are good anti- 
hypertensive agents. The clinical profile of a vasodilator 
depends on its effect on the venous return, cardiac out- 
put, regional blood flow, renin-angiotensin system, and 
sympathetic reflexes. From the viewpoint of hemody- 
namics, an ideal antihypertensive drug is a vasodilator 
that does not excessively increase cardiac output, causes 
no fluid retention, does not induce a great deal of venodi- 
lation, and does not elicit substantial neurohumoral 
counterregulation. Angiotensin-converting-enzyme in- 
hibitors, some calcium antagonists, and some combined 
alpha/beta-blocking agents come close to satisfying the 
hemodynamic definition of an ideal antihypertensive 
drug. 
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A general scheme of hemodynamics is given in Fig. 1 [1], 
Blood pressure is a product of cardiac output and vascular 
resistance, shown on the vertical and horizontal lines. The 
vascular resistance, shown with diagonal isoresistance 
lines, can be calculated by dividing the mean blood pres- 
sure by the cardiac output. It follows from the graph that 
the blood pressure can be decreased either by a fall in car- 
diac output or by a decrease in the vascular resistance. In 
established hypertension, high pressure is due to an in- 
crease in vascular resistance [2]. Since vasodilators dimin- 
ish the high resistance, it is hypothesized that they reduce 
the pressure through a physiologic mechanism. Within the 
context of such thinking, drugs that decrease blood pres- 
sure through a fall in cardiac output have a physiologically 
undesirable effect. 
Such reasoning, logical as it may be, is a great 
oversimplification; much depends on the circumstan- 
ces. The notion that decreased cardiac output and 
increased vascular resistance is unhealthy will be a 
surprise to anybody vaguely familiar with the hemody- 
namic adjustment to upright posture. Cardiac output is 
much lower than in recumbency and the resistance is 
high, but reports on specific cardiovascular morbidity of 
upright posture are nonexistent. Similarly, a decrease in 
vascular resistance is not always good; hypertensive 
encephalopathy is associated with a great increase in 
cerebral blood flow [3]. Before endorsing vasodilators or 
condemning drugs that reduce the cardiac output, one 
must know much more about each of these compounds 
and about the prevailing conditions under which they are 
given. 
Vasodilation: at which level of cardiac output? 
The distinction between vasodilating and cardiac out- 
put lowering drugs becomes even more moot when one 
takes into account that the simple formula (blood pres- 
sure=cardiac output xvascular resistance), while de- 
scribing the physical components of the hemodynamic 
relationship, is not directly applicable to the living organ- 
ism. Under a wide range of circumstances (upright 
posture, bleeding, acute intravenous beta-blockade), the 
fall in cardiac output is met with an increase in vascular 
resistance while the blood pressure remains unchanged. 
A pharmacologic decrease in cardiac output leads 
to lower pressures only if the compensatory increase 
in resistance fails to materialize. An example is given in 
Fig.2, adapted from a study by Hansson et al. [4]. 
Treatment with propranolol did not decrease every- 
body's blood pressure but, regardless of their blood 
pressure responses, all patients showed a decrease in car- 
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Fig. 1. The pressure-flow-resistance relationship. The diagonal lines 
are lines of isoresistance, with the lowest representing low resistance 
and the highest, high resistance. Note that the vascular caliber at low 
resistance is larger and that small increases in pressure cause a large 
increase in flow. At the high resistance line, the vascular caliber is 
narrow and a large increase in pressure causes only a small increase 
in flow. The horizontal vector represents a decrease in flow, associ- 
ated with an increase in resistance and no change in pressure. The di- 
agonal, downwardly pointing vector represents a decrease in flow, 
with an unchanged resistance and a fall in blood pressure 
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Fig.2. Hemodynamic effect of chronic beta-adrenergic blockade 
with propranolo]. (Data adapted from Hansson et al. [4]). The pa- 
tients are divided into responders (solid line) and nonresponders 
(broken line). The full circle at the base of the arrow presents the 
hemodynamic state before the treatment and the head of the arrow, 
the hemodynamics after 4 weeks of treatment with 160-320 mg pro- 
pranolol. Note that the non-responder group actually showed a 
larger decrease in the cardiac index, but this was met by an increase 
in vascular resistance and the blood pressure did not change. In re- 
spenders, the fall of the cardiac index did not elicit an increase of re- 
sistance and the blood pressure fell. Note that on propranolol both 
groups had low cardiac indexes, but the responder group had sub- 
stantially lower vascular resistance. 
- Responders; . . . . .  non-responders 
diac output. When responders and nonresponders are 
compared, the real difference is that responders had 
much lower levels of vascular resistance, which means 
that they were relatively more vasodilated than the non- 
responders. It follows that all antihypertensive agents are 
vasodilators, but the dilation occurs at different levels of 
cardiac output. 
The low cardiac output-low vascular resistance state 
seen with beta-adrenergic blockade is not intrinsically 
deleterious, but some of its clinical consequences can be 
disturbing. At  rest and at moderate levels of exercise, the 
tissues continue to receive adequate oxygen supplies 
through increased oxygen extraction from the blood. 
During more strenuous exercise, beta-blocked patients 
cannot increase their cardiac output and experience the 
onset of fatigue. Good clinicians take into account this 
hemodynamic limitation and beta-blocking agents are 
not given to patients who regularly engage in endurance 
exercise. 
The hemodynamic picture at the opposite pole, when 
the cardiac output is high, can be equally disturbing. In 
spite of the lower afterload, the large increase in cardiac 
output increases the overall cardiac work and patients 
with decreased coronary reserve may develop a variety of 
ischemic syndromes. 
What is being vasodilated? 
Vasoconstrictive or vasodilating stimuli elicit very diverse 
responses along different segments of the vascular tree. 
Veins are different from arteries in regard to both the vas- 
cular geometry and the contractile properties of the 
smooth muscles. The wall-to-lumen ratio in the resistance 
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vessels is much larger, and vasodilation causes a large 
change in the vascular resistance. A similar decrease in 
venous smooth-muscle contraction does not affect the re- 
sistance; the response is a large increase in vascular capac- 
ity. The balance between hemodynamic changes in the 
resistance and capacitance vessels determines the level of 
cardiac output. 
A drug causing only arteriolar dilatation, with no in- 
crease in venous capacity, reduces the blood pressure but 
simultaneously increases the cardiac output. As men- 
tioned above, an excessive cardiac output may have nega- 
tive clinical effects. A predominant venodilator decreases 
the preload and thereby reduces the cardiac output. This 
is particularly bothersome in the upright posture, since ex- 
cessive gravitational pooling of blood frequently causes 
orthostatic hypotension. A schematic overview of the ef- 
fect of various classes of vasodilators on cardiac output is 
given in Fig. 3. 
Veins and arterioles are morphologically very differ- 
ent, and it is easy to visualize why they would be function- 
ally different. The morphology of arterioles across the 
whole body is rather uniform. Nevertheless, arterioles 
show a great range of functional differences and their re- 
sponse to vasodilators varies from organ to organ. These 
differences in regional vasodilation must be taken into 
consideration when one evaluates the clinical profile of a 
vasodilator. Unpleasant flushing and peripheral edema 
with some calcium antagonists, as well as headaches with 
hydralazine, reflect the excessive regional vasodilation 
caused by these compounds. The substantial fluid reten- 
tion observed with minoxidil is in large part caused by un- 
favorable redistribution of the renal blood flow. 
Which compensatory  responses are elicited? 
Vasodilation triggers a number of counterregulatory re- 
sponses; some of them directly oppose the vasodilation, 
whereas others strive to maintain an unchanged blood 
pressure. The pressure-preserving mechanisms of particu- 
lar interest are sympathetic cardiostimulation, fluid reten- 
tion, and activation of the renin-angiotensin system. 
Acute vasodilation inevitably elicits reflex increases 
in the heart rate and stroke volume. In addition to the 
aforementioned balance between dilatation of the veins 
and arterioles, this reflex cardiostimulation largely deter- 
mines the degree of elevation of the cardiac output. This 
increased sympathetic drive may have a specific negative 
effect on the heart. The issue evolves around the so- 
called trophic effect of the sympathetics. Whereas the in- 
crease in blood pressure mechanically elicits cardiac and 
vascular hypertrophy, the degree of hypertrophy depends 
on various other "growth" factors. Denervated blood 
vessels fail to develop vascular hypertrophy [5, 6]. In 
spontaneously hypertensive rats, reflex-inducing vasodi- 
lators (hydralazine and minoxidil) decrease the blood 
pressure but fail to reduce the left ventricular hyper- 
trophy [7]. Rats treated with a sympatholytic agent (cz- 
methyldopa) showed significant reduction of the left ven- 
tricular wall mass in spite of poorer blood pressure 
control. Noradrenaline facilitates the growth of cardiac 
myocytes in isolated culture [8]. This effect appears to be 
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regulated through alpha-adrenergic adrenoreceptors. 
Left ventricular hypertrophy is a strong risk factor for fu- 
ture blood-pressure-related mortality and morbidity. 
Since reflex-inducing vasodilators favor ventricular 
hypertrophy, they are not the preferred treatment of 
choice for hypertension. 
Fluid retention is another potent counterregulatory 
mechanism to offset the hypotensive effect of vasodila- 
tors. This is due in part to the redistribution of the 
intrarenal blood flow, but activation of the renin-an- 
giotensin system also plays a major role. If the fluid 
retention is not prevented, a vasodilator will lose its in- 
itial efficacy. Drugs that directly antagonize the renin- 
angiotensin system (converting enzyme inhibitors) or 
prevent the reflex increase in renin (combined vaso- 
dilators-beta-blockers) greatly obviate the problem. Cal- 
cium antagonists also cause little fluid retention as, in ad- 
dition to causing vasodilation, they also directly increase 
diuresis. 
What is an ideal vasodilator? 
Vasodilators are not a homogeneous group of compounds 
with uniformly advantageous features. To be efficacious 
and useful, a vasodilator must fulfill certain criteria: 
1. Vasodilation should occur at a normal level of cardiac 
output; levels that are either too low or too high are unde- 
sirable. 
2. The vasodilator should not cause excessive blood flow 
in the skin or in other nonessential organs. 
3. Renal blood flow should not be reduced. 
4. There should be little or no fluid retention. 
5. Vasodilators should either not elicit or be capable of 
abolishing sympathetic counterregulatory responses. 
6: The vasodilator should not cause excessive venodilation. 
Three major groups of contemporary vasodilators 
meet most of these criteria: converting enzyme inhibi- 
tors, some calcium antagonists, and combined 
alpha/beta-adrenergic blocking agents. Converting 
enzyme inhibitors are not direct vasodilators; rather, they 
remove the angiotensin-mediated vasoconstriction. 
Nevertheless, the end result is a decrease in vascular re- 
sistance. This decrease is not associated with tachycardia 
or with an increase in plasma norepinephrine [9]. Con- 
verting enzyme inhibitors antagonize the effect of an- 
giotensin on aldosterone and thereby prevent sodium 
and fluid retention. 
Dihydropiridine-type calcium antagonists are potent 
peripheral vasodilators and elicit very strong sympathetic 
responses. The clinical side effects of headache, tachycar- 
dia, and flushing can limit their usefulness. Diltiazem and 
verapamil-like drugs, although generally less efficacious 
as dilators, can prevent tachycardia; they are also 
mild diuretics. When edema occurs, this is due to fluid re- 
distribution from the intravascular to the interstitial 
space and not to generalized fluid retention. Absence of 
both fluid retention and tachycardia are desirable fea- 
tures. 
Combined alpha- and beta-adrenergic blocking agents 
are a welcome addition to our antihypertensive armamen- 
tarium. Their alpha-adrenergic blocking action is respon- 
s 128 
sible for vasodilation, whereas the beta-blocking compo- 
nent adds other desirable features. Blockade of cardiac 
and renal beta-adrenergic  receptors prevents tachycardia 
and the renin-angiotensin-induced sodium retention. The 
clinical efficacy of these compounds depends on whether  
the duration and potency of the alpha- and beta-adrener-  
gic component  at a given dose are well balanced. Other  
ancillary propert ies  such as the magnitude of the venous 
effect and the presence of intrinsic sympathomimet ic  ac- 
tivity are also important .  These differences require that  
each new compound in this class be examined in its own 
right. The drug that is the subject of this symposium, car- 
vedilol, has a number  of attractive properties.  The vasodi- 
lation in the skin and muscles is not excessive, the de- 
crease in peripheral  resistance occurs at normal  levels of 
cardiac output,  and there is no evidence of excessive ve- 
nodilation or fluid retention. 
The efforts of the pharmaceutical  industry to bring 
new compounds to the marke t  may confuse the practic- 
ing physician with new names and doses to learn. 
However,  many of these compounds offer a true advant- 
age. General ly  speaking, the more  uniform a class 
of drugs (diuretics, converting enzyme inhibitors), 
the less likely it is that a new compound will be truly 
different. However,  within the class of combined 
beta- and alpha-blocking agents, much depends on the 
balance between various characteristics of these 
multiple-action compounds.  The impressive dossier of 
clinical trials and some of the interesting features of car- 
vedilol make  it a compound well worth consideration in 
everyday practice. 
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